Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia
We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants who showed improvements in multilineage blood cell counts, even with daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT05832216.
Authors
- Neng Nie
- Jinbo Huang (ORCID: https://orcid.org/0000-0003-0902-6357)
- Yuechen Luo (ORCID: https://orcid.org/0000-0001-8912-1818)
- Lele Zhang
- Weiwang Li
- Jun Shi (ORCID: https://orcid.org/0000-0002-8531-0483)
- Xiao Yu (ORCID: https://orcid.org/0000-0001-9441-1705)
- Meili Ge (ORCID: https://orcid.org/0000-0002-8229-4203)
- Jianping Li (ORCID: https://orcid.org/0000-0002-5392-0471)
- Ruonan Li (ORCID: https://orcid.org/0000-0002-9581-2620)
- Yu Lian
- Zhen Gao
- Hong Pan (ORCID: https://orcid.org/0000-0002-5603-9903)
- Yizhou Zheng (ORCID: https://orcid.org/0000-0001-5939-7549)
- Jingyu Zhao (ORCID: https://orcid.org/0009-0000-0989-6593)
- Yuan Li (ORCID: https://orcid.org/0000-0002-0284-5854)
- Liwei Fang
- Zhexiang Kuang
- Xin Zhao (ORCID: https://orcid.org/0000-0003-2874-3300)
Institutions
- Academy of Medical Sciences (GB)
- Shanxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Shanxi Academy of Medical Sciences (CN)
Publication Details
- Journal
- Blood
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1182/blood.2025029006
- Citations
- 2
- Primary Topic
- Calcium signaling and nucleotide metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.24